Nextgen Healthcare Inc (NASDAQ:NXGN) – Research analysts at Piper Jaffray Companies issued their Q1 2020 earnings per share estimates for shares of Nextgen Healthcare in a research note issued to investors on Wednesday, May 29th, Zacks Investment Research reports. Piper Jaffray Companies analyst S. Wieland anticipates that the company will post earnings per share of $0.15 for the quarter. Piper Jaffray Companies also issued estimates for Nextgen Healthcare’s Q2 2020 earnings at $0.23 EPS, Q3 2020 earnings at $0.16 EPS, Q4 2020 earnings at $0.13 EPS, FY2020 earnings at $0.67 EPS, Q2 2021 earnings at $0.27 EPS, Q3 2021 earnings at $0.21 EPS, Q4 2021 earnings at $0.22 EPS and FY2021 earnings at $0.90 EPS.
Nextgen Healthcare (NASDAQ:NXGN) last issued its quarterly earnings results on Tuesday, May 28th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.01. Nextgen Healthcare had a return on equity of 11.03% and a net margin of 4.63%. The company had revenue of $134.80 million during the quarter, compared to analyst estimates of $133.35 million. Nextgen Healthcare’s revenue for the quarter was down .7% on a year-over-year basis.
A number of other research analysts have also commented on the company. TheStreet upgraded Nextgen Healthcare from a “c+” rating to a “b” rating in a report on Tuesday, May 28th. Dougherty & Co lowered Nextgen Healthcare from a “buy” rating to a “neutral” rating in a report on Wednesday, May 29th. Zacks Investment Research upgraded Nextgen Healthcare from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Friday, April 26th. Svb Leerink upgraded Nextgen Healthcare from a “market perform” rating to an “outperform” rating and upped their target price for the company from $19.00 to $22.00 in a research note on Thursday, April 25th. Finally, Leerink Swann upgraded Nextgen Healthcare from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Nextgen Healthcare has an average rating of “Hold” and a consensus target price of $19.50.
Shares of NXGN stock traded down $0.19 during trading hours on Monday, reaching $18.73. 249,609 shares of the company’s stock were exchanged, compared to its average volume of 256,739. Nextgen Healthcare has a fifty-two week low of $13.89 and a fifty-two week high of $23.73. The company has a market capitalization of $1.21 billion, a PE ratio of 30.70, a P/E/G ratio of 3.24 and a beta of 1.06. The business’s fifty day simple moving average is $19.18. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 0.03.
In other Nextgen Healthcare news, Director George H. Bristol sold 13,873 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $19.25, for a total transaction of $267,055.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sheldon Razin sold 4,018 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $19.06, for a total value of $76,583.08. The disclosure for this sale can be found here. Insiders sold 19,004 shares of company stock valued at $364,819 over the last 90 days. 17.90% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in NXGN. Norges Bank acquired a new position in Nextgen Healthcare during the fourth quarter worth $25,675,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of Nextgen Healthcare by 40.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 493,009 shares of the company’s stock worth $8,297,000 after purchasing an additional 143,105 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Nextgen Healthcare during the fourth quarter worth $2,158,000. JPMorgan Chase & Co. bought a new stake in shares of Nextgen Healthcare during the third quarter worth $2,698,000. Finally, Kennedy Capital Management Inc. grew its holdings in shares of Nextgen Healthcare by 33.5% during the first quarter. Kennedy Capital Management Inc. now owns 514,571 shares of the company’s stock worth $8,660,000 after purchasing an additional 129,082 shares during the last quarter. Hedge funds and other institutional investors own 69.96% of the company’s stock.
Nextgen Healthcare Company Profile
NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company’s principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.